Silodosin Capsule Direct Compression Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical formulation of silodosin faces challenges due to its physical properties, including incompatibilities with excipients, degradation issues, and difficulties in achieving stable and uniform dosage forms, particularly in tablet and capsule forms, which require complex and costly wet granulation processes.
Innovation Solution
A pharmaceutical composition comprising silodosin, a surfactant, a lubricant, and a disintegrant, specifically low-substituted hydroxypropyl cellulose (L-HPC) in high amounts, blended in a single powder mixture and filled directly into capsules, bypassing granulation and additional stabilizers, to enhance stability and uniformity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If wet granulation process is used to prepare silodosin formulations, then content uniformity and dissolution properties are improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent extracts and eliminates the wet granulation step from the manufacturing process. By using direct compression with a simplified blend of excipients (lactose, pregelatinized starch, magnesium stearate), the formulation achieves acceptable content uniformity without the complex granulation equipment and multi-step process required by conventional methods.
Solution Approach 2:
The patent segments the manufacturing process into simpler discrete steps: mixing the API with excipients in a single powder mixture, optional drying if necessary, and direct compression into tablets. This segmentation removes the complex wet granulation sub-steps while maintaining product quality.
2Manufacturing precision
If wet granulation process is used to prepare silodosin formulations, then dissolution properties are improved, but manufacturing time and cost increase
Solution Approach 1:
The patent performs preliminary action by pre-mixing the silodosin with excipients that inherently provide good dissolution properties (pregelatinized starch as disintegrant, lactose as filler). This preliminary blending eliminates the need for time-consuming wet granulation and subsequent drying steps, achieving acceptable dissolution directly through proper excipient selection and mixing.
3Ease of operation
If lubricants are added to silodosin formulations, then handling properties are improved, but dissolution time increases
Solution Approach 1:
The patent changes the parameters of the formulation by using a high proportion of pregelatinized starch (15-30% w/w) as a disintegrant that counteracts the dissolution-retarding effect of lubricants. The magnesium stearate is used at a controlled low level (0.5-2% w/w) and the blend is compressed immediately after mixing to minimize lubricant interference with dissolution, achieving both good handling and acceptable dissolution.
4Quantity of substance
If silodosin is formulated with lactose, then filler properties are improved, but dissolution and hardness properties deteriorate
Solution Approach 1:
The patent creates a composite material system combining lactose (as filler), pregelatinized starch (as disintegrant and binder), and magnesium stearate (as lubricant). This composite excipient blend compensates for lactose's negative effects: pregelatinized starch provides disintegration and binding properties that improve hardness and dissolution, while lactose maintains its excellent filler and flow properties. The synergistic combination achieves overall formulation improvement.
Data Source
AI summary
The invention relates to a pharmaceutical composition in the form of a capsule, comprising a powder mixture comprising silodosin. The invention also relates to the use of said formulation in the treatment of dysuria and/or benign prostatic hyperplasia and to a method for the manufacture of the composition comprising mixing the excipients and silodosin in a single powder mixture or blend and direct filling into a capsule.